medigraphic.com

2010, Number 2

<< Back Next >>

Rev Med Inst Mex Seguro Soc 2010; 48 (2)

Incidence and trends of neuroblastoma in Mexican children attending at Instituto Mexicano del Seguro Social

Palma-Padilla V, Juárez-Ocaña S, González-Miranda G, Siordia-Reyes AG, Mejía-Aranguré JM, Carreón-Cruz R, Fajardo-Gutiérrez A

Language: Spanish
References: 35
Page: 151-158
PDF size: 46.16 Kb.


ABSTRACT

Background: neuroblastoma (NB) is the principal tumor of the sympathetic nervous system in children. Objective: to describe the epidemiological and clinical characteristics of Mexican children with NB.
Methods: a population-based, prolective study, with data obtained from the Childhood Cancer Registry of the Instituto Mexicano del Seguro Social. The frequencies and incidence of the variables of the study were obtained by age and sex. The trend was calculated with the annual percentage of change.
Results: of a total of 2758 children with cancer, 72 (2.6 %) were identified in the Group IV, according to the International Classification of Childhood Cancer. The average incidence for NB was 3.8, the highest incidence was found in Guerrero. NB was highest in the group under one year of age (18.5). The male/ female ratio was 1.1 and there was no trend toward an increase. Stages III and IV were presented in 88 % of the cases. There was no association between the stages, the age at the TD, or the histological pattern.
Conclusions: it is possible that the low incidence of NB in Mexican children is due to the difficulty in early diagnosis due the majority of the cases was diagnosed in the advanced stages.


REFERENCES

  1. Brodeur GM, Maris JM. Neuroblastoma. En: Pizzo PA, Poplack DG, editores. Principles and practice of pediatric oncology. Fourth edition. Philadelphia, USA: Lippincott Williams & Wilkins; 2002. p. 895- 937.

  2. Spix C, Pastore G, Sankila R, Stiller CHA, Steliarova- Foucher E. Neuroblastoma incidence and survival in European children (1978-1997): report from the automated childhood cancer information system project. Eur J Cancer 2006;42:2081-2091.

  3. Steliarova-Foucher E, Stiller CA, Lacour B, Kaatsch P. International Classification of Childhood Cancer. Cancer 2005;103:1457-1467.

  4. Goodman MT, Gurney JG, Smith MA, Olshan AF. Sympathetic nervous system tumors. En: Ries LAG, Smith MA, Gurney JG, Linet M, Tamra T, Young JL, editores. Cancer incidence and survival among children and adolescents: United States SEER Program 1975-1995. Bethesda, MD: National Cancer Institute, NIH Pub. No. 99-4649; 1999. p. 65-72.

  5. Parkin DM, Kramárová E, Draper GJ, Masuyer E, Michaelis J, Neglia J, et al. International incidence of childhood cancer, vol. II. Lyon: IARC Scientific Publication No. 144; 1998.

  6. Fajardo-Gutiérrez A, Juárez-Ocaña S, González- Miranda G, Palma-Padilla V, Carreón-Cruz R, Ortega-Álvarez M, et al. Incidence of cancer in children residing in ten jurisdictions of the Mexican Republic: importance of the cancer registry (a population-based study). BMC Cancer 2007; 7:68. Disponible en http://www.biomedcentral. com/1471-2407/7/68

  7. Fritz A, Percy C, Jack A, Shanmugaratnam K, Sobin L, Parkin DM, Whelan S. International Classification of Diseases for Oncology. Third edition. Geneva: World Health Organization; 2000.

  8. Brodeur GM, Pritchard J, Berthold F, Carlsen NL, Castel V, Castelberry RP, et al. Revisions in the international criteria for neuroblastoma diagnosis, staging and response to treatment in patients with neuroblastoma. J Clin Oncol 1993;11:1466- 1477.

  9. Evans AE, D’Angio GJ, Randolph JA. A proposed staging for children with neuroblastoma. Children´s Cancer Group Neuroblastoma Staging System A. Cancer 1971;27:374-378.

  10. Peuchmaur M, d’Amore ESG, Joshi VV, Hata J, Roald B, Dehner LP, et al. Revision of the International Neuroblastoma Pathology Classification. Confirmation of favorable and unfavorable prognostic subsets in ganglioneuroblastoma, nodular. Cancer 2003;98:2274-2281.

  11. Kramárová E, Stiller C, Ferlay J, Parkin DM, Draper GJ, Michaelis J, et al. Child-Check Program. Lyon: IARC Technical Report no. 9; 1996. p. 43-47.

  12. Dirección de Prestaciones Médicas. Estructura de la población adscrita a médico familiar de 1996- 2005. México: IMSS; 2005.

  13. Smith PG. Comparison between registries: age-standardized rates. En: Parkin DM, Muir CS, Whelan SL, Gao YT, Ferlay J, Powell J, editores. Cancer incidence in five continents. Lyon: IARC Scientific Publication No. 120, vol. 6; 1992. p. 865-870.

  14. Ries LAG, Melbert D, Krapcho M, Mariotto A, Miller BA, Feuer EJ, et al. SEER cancer statistics review, 1975-2004. Bethesda, MD: National Cancer Institute; 2007. Disponible en http://seer. cancer.gov/csr/1975_2004/

  15. Kirkwood BR, Sterne AC. Essential medical statistics. Oxford: Blackwell Science; 2003.

  16. Fajardo-Gutiérrez A, Navarrete-Martínez A, Reynoso- García M, Zarzosa-Morales ME, Mejía- Aranguré M, Yamamoto-Kimura LT. Incidence of malignant neoplasms in children attending social security hospitals in Mexico City. Med Pediatr Oncol 1997;29:208-212.

  17. Torres PB, Graupera MB, Ravelo BF, García MJ, Rodríguez AS, Ropero RT. Incidencia del cáncer pediátrico en la provincia sanitaria de Cuba (1990- 1994). Rev Cubana Oncol 1999;15:103-207.

  18. Valsecchi MG, Tognoni G, Bonilla M, Moreno N, Baez F, Pacheco C, et al. Clinical epidemiology of chilhood cancer in Central America and Caribbean countries. Ann Oncology 2004;15:680-685.

  19. Ocheni S, Bioha FI, Ibegbulam OG, Emodi IJ, Ikefuna AN. Changing pattern of childhood malignancies in Eastern Nigeria. West Afr J Med 2008; 27:3-6.

  20. Sancho-Garnier H, D’Angio GJ. Report of the 1998 Consensus Conference on Neuroblastoma Screening. Med Ped Oncol 1999;33:357-359.

  21. Frisch LP, Kerbl R, Lackner H, Urban Ch. “Wait and see” strategy in localized neuroblastoma in infants: an option not only for cases detected by mass screening. Pediatr Blood Cancer 2004;43: 679-682.

  22. Oue T, Inoue M, Yoneda A, Kubota A, Okuyama H, Kawahara H, et al. Profile of neuroblastoma detected by mass screening, resected after observation without treatment: results of the wait and see pilot study. J Pediatr Surg 2005;40:359-363.

  23. Breslow N, McCann B. Statistical estimation of prognosis for children with neuroblastoma. Cancer Res 1971;31:2098-2103.

  24. Simon T, Spitz R, Faldum A, Hero B, Berthold F. New definition of low-risk neuroblastoma using stage, age and 1p and MYCN status. J Pediatr Hematol Oncol 2004;26:791-796.

  25. Friedman G K, Castleberry RP. Changing trends of research and treatment in infant neuroblastoma. Pediatr Blood Cancer 2007;49:1060-1065.

  26. Powell JE, Estéve J, Mann J R, Parker L, Frappaz D, Michaelis J, et al. Neuroblastoma in Europe: differences in the pattern of disease in the UK. Lancet 1998;352:682-687.

  27. Feltbower RG, Lewis IJ, Picton S, Richards M, Glasser AW, Kinsey SE, et al. Diagnosing childhood cancer in primary care. A realistic expectation? Br J Cancer 2004;90:1882-1884.

  28. Glaser ER, Perkins CI, Young JL, Schlag RD, Campleman SL, Wright WE. Cancer among Hispanic children in California 1988-1994. Cancer 1999;86:1070-1079.

  29. Wilkinson JD, González A, Wohler-Torres B, Fleming LE, MacKinnon J, Trapido E, et al. Cancer incidence among Hispanic children in the United States. Rev Panam Salud Publica 2005;18:5-23.

  30. Dalmasso, Pastore G, Zuccolo L, Maule M-M, Pearce N, Merletti F, et al. Temporal trends in the incidence of childhood leukemia, lymphomas and solid tumors in north-west Italy, 1967-2001. A report of the Childhood Cancer Registry of Piedmont. Haematologica 2005;90:1197-1204.

  31. Schüz J, Kaletsch U, Meinert R, Kaatsch P, Spix C, Michaelis J. Risk factors for neuroblastoma at different stages of disease. Results from a population- based case-control study in Germany. J Clin Epidemiology 2001;54:702-709.

  32. National Cancer Institute. Neuroblastoma (PDQ): Treatment. Disponible en http://www.cancer.gov/ cancertopics/pdq/treatment/neuroblastoma/Health- Professional/page1

  33. Papaioannou G, McHugh K. Neuroblastoma in childhood: review and radiological findings. Cancer Imaging 2005;5:116-127.

  34. López-Aguilar E, Cerecedo-Díaz F, Rivera-Márquez H, Valdéz-Sánchez M, Sepúlveda-Vildósola AC, Delgado-Huerta S, et al. Neuroblastoma: factores pronósticos y sobrevida. Experiencia en el Hospital de Pediatría del Centro Médico Nacional Siglo XXI y revisión de la literatura. Gac Med Mex 2003; 39:209-214.

  35. Shojaei-Brosseau T, Chompret A, Abel A, de Vathaire F, Raquin MA, Brugieres L, et al. Genetic epidemiology of neuroblastoma: a study of 426 cases at the Institut Gustave-Roussy in France. Pediatr Blood Cancer 2004;42:99-105.




2020     |     www.medigraphic.com